Medical management of Crohn's disease

Drugs of Today

Volumn 34, Issue 6, 1998, Pages 541-548

  Stein, Robert B ^a,c   Hanauer, Stephen B ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; SALAZOSULFAPYRIDINE; STEROID;

CROHN DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DEPENDENCE; HUMAN; RECURRENT DISEASE; REMISSION; REVIEW; SURGICAL APPROACH;

EID: 0031822799     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.6.485252     Document Type: Review

References (73)

1. Hanauer, S.B., Meyers, S. Practice guidelines: Management of Crohn's disease in adults. Am J Gastroenterol 1997, 92: 559-66.
2. Elton, E., Hanauer, S.B. Review article: The medical management of Crohn's disease. Aliment Pharmacol Ther 1996, 10: 1-22.
3. Feagan, B.G., McDonald, J.W., Koval, J.J. Therapeutics and inflammatory bowel disease: A guide to the interpretation of randomized controlled trials. Gastroenterology 1996, 110: 275-83.
4. Malchow, H., Ewe, K., Brandes, J.W. et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984, 86: 249-66.
5. Summers, R.W., Switz, D.M., Sessions, J.T. Jr. et al. National Cooperative Crohn's Disease Study (NCCDS): Results of drug treatment. Gastroenterology 1979, 77: 847-69.
6. Hanauer, S.B., Stathopoulos, G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Safety 1991, 6: 192-219.
7. Das, K.M., Eastwood, M.A., McManus, J.P. et al. Adverse reactions during salicylazosul-fapyridine therapy and the relation with drug metabolism and acetylator phenotype. New Engl J Med 1973, 289: 491.
8. Taffet, S.L., Das, K.M. Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 1983, 28: 833.
9. Hanauer, S.B. Drug therapy: Inflammatory bowel disease. New Engl J Med 1996, 334: 841-8.
10. Hanauer, S.B., Meyers, S., Sachar, D.B. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease. In: Inflammatory Bowel Disease, 4th Ed. Kirsner, J.B., Shorter R.G. (Eds.). Williams & Wilkins: Baltimore 1995, 643-63.
11. Singleton, J.W., Hanauer, S.B., Gitnick, G.L. et al. and the Pentasa Crohn's Disease Study Group. Mesalamine capsules for the treatment of active Crohn's disease. Results of a 16 week trial. Gastroenterology 1993, 104: 1293-301.
12. Hanauer, S.B., Baert, F. Medical therapy of inflammatory bowel disease. Med Clin North Am 1994, 78: 1413-26.
13. Mahida, Y.R., Jewell, D.P. Slow-release 5-amino-salicylic acid (Pentasa®) for the treatment of active Crohn's disease. Digestion 1990, 45: 88-92.
14. Rasmussen, S.N., Lauritsen, K., Tage-Jensen, U. et al. 5-Aminosalicylic acid in the treatment of Crohn's disease: A 16-week double-blind, placebo-controlled, multicentre study with Pentasa®. Scand J Gastroenterol 1987, 22: 877-83.
15. Wright, J.P., Jewell, D.P., Modigliani, R. et al. A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Inflamm Bowel Dis 1996, 1: 241-6.
16. Brandt, L.J., Bernstein, L.H., Boley, S.J. et al. Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 1982, 83: 383-7.
17. Ursung, B., Alm, T., Barany, F. et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The Cooperative Crohn's Disease Study in Sweden. Gastroenterology 1982, 83: 550-62.
18. Sutherland, L., Singleton, J., Sessions, J. et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991, 32: 1071-5.
19. Duffy, L.F., Daum, F., Fisher, S.E. et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985, 88: 681-4.
20. Turunen, U., Farkkila, V., Valtonen, V., Seppala, K. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease. Gastroenterology 1993, 104: A793.
21. Colombel, J.F., Lemann, M., Cassagnou, M. et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Gastroenterology 1997, 112: A951.
22. Prantera, C., Zannoni, F., Scribano, M.L. et al. Metronidazole plus ciprofloxacin for the treatment of active Crohn's disease: A randomized controlled trial. Am J Gastroenterol 1996, 91: 328-32.
23. Modigliani, R., Mary, Y.-J., Simon, J.F. et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease: Evolution on prednisolone. Gastroenterology 1990, 98: 811-8.
24. Munkholm, P., Langholz, E., Davidsen, M. et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35: 360-2.
25. Rutgeerts, P., Lofberg, R., Malchow, H. et al. A comparison of budesonide with prednisolone for active Crohn's disease. New Engl J Med 1994, 331: 842-5.
26. Greenberg, G.R., Feagan, G.B. et al. and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. New Engl J Med 1994, 331: 836-41.
27. Thomsen, O., Cortot, A., Jewell, D. et al. Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week international randomized, double-blind multicenter trial. Gastroenterology 1997, 112: A1104.
28. Greenberg, G.R., Feagan, B.G., Martin, F. et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996, 110: 45-51.
29. Hellers, G., Lofberg, R., Rutgeerts, P. et al. Oral budesonide following ileocecal resection of Crohn's disease. A one-year placebo-controlled study. Gastroenterology 1996, 110: A923.
30. Modigliani, R., Colombel, J.F., Dupas, L. et al. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance. Gastroenterology 1996, 110: 688-93.
31. Turunen, U., Farkkila, M., Kakala, K. et al. Ciprofloxacin treatment combined with conventional therapy in Crohn's disease: A prospective, double-blind, placebo controlled trial. Gut 1995, 37: A193.
32. Lewis, J.D., Fisher, R.L. Nutrition support in inflammatory bowel disease. Med Clin North Am 1994, 78: 1443-56.
33. Seidman, E.G., Boutillier, L., Weber, A.M. et al. Elemental diet versus prednisone as primary treatment of Crohn's disease. Gastroenterology 1986, 90: A1625.
34. Hawthorne, A.B., Hawkey, C.J. Immunosuppressive drugs in inflammatory bowel disease: A review of their mechanisms of efficacy and place in therapy. Drugs 1989, 38: 267-88.
35. Cohen, R.D., Hanauer, S.B. Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Curr Opin Gastroenterol 1995, 11: 321-30.
36. Ewe, K., Press, A.G., Singe, C. et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993, 105: 367-72.
37. Pearson, D.C., May, G.R., Fick, G.H., Sutherland, J.R. Azathioprine and 6-MP in Crohn's disease. A meta-analysis. Ann Intern Med 1995, 122: 132-42.
38. Present, D.H., Korelitz, B.I., Wisch, N. et al. Treatment of Crohn's disease with 6-mercaptopurine: A long-term randomised, double-blind study. New Engl J Med 1981, 302: 981-7.
39. Present, D.H., Meltzer, S.J., Krumholz, M.P. et al. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long term toxicity. Ann Intern Med 1989, 111: 641-9.
40. Connell, W.R., Kamm, M.A., Dickson, M. et al. Long-term neoplasia risk after azathioprine treatment of inflammatory bowel disease. Lancet 1994, 343: 1249-52.
41. Haber, D.J., Meltzer, S.J., Present, D.H. et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986, 91: 982-6.
42. Connell, W.R., Kamm, M.A., Ritchie, U.K. et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34: 1081-5.
43. Kozorek, R.A., Patterson, D.J., Gelfand, M.D. et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110: 353-6.
44. Feagan, B.G., Rochon, J., Fedorak, R.N. et al. Methotrexate for the treatment of Crohn's disease. New Engl J Med 1995, 332: 292-7.
45. Weinblatt, B.E. Methotrexate for chronic disease in adults. New Engl J Med 1995, 332: 330-1.
46. Morgan, S.L., Baggott, J.E., Vaughn, W.H. et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994, 121: 833-41.
47. Fazio, V.W., Strong, S.A. The surgical management of Crohn's disease. In: Inflammatory Bowel Disease, 4th Ed. Kirsner, J.B., Shorter, R.G. (Eds.). Williams & Wilkins: Baltimore 1995, 830-87.
48. Sandborn, W.J., Tremaine, W.J. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc 1992, 67: 981-90.
49. Sandborn, W.J. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1: 48-63.
50. Hanauer, S.B., Smith, M.B. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993, 88: 646-9.
51. Present, D.H., Lichtiger, S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994, 39: 374-80.
52. Stein, R., Cohen, R., Hanauer, S. Complications during cyclosporine therapy for inflammatory bowel disease. Gastroenterology 1997, 112: A1096.
53. Sternthal, M., George, J., Kornbluth, A. et al. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease. Gastroenterology 1996, 110: A1019.
54. Sandborn, W.J. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91: 423-33.
55. Sachar, D.B. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995, 20: 117-22.
56. Messori, A., Brignola, C., Trallori, G. et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 1994, 89: 692-8.
57. Brignola, C., Cottone, M., Pera, A. et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1994, 108: 345-9.
58. Mahaderan, U., Marion, J.F., Present, D.H. The place for methotrexate in the treatment of refractory Crohn's disease. Gastroenterology 1997, 112: A1031.
59. Zenjari, T., Lemann, M., Mesnard, B. et al. Methotrexate in Crohn's disease: Long-term efficacy and toxicity. Gastroenterology 1996, 110: A1053.
60. Belluzzi, A., Campieri, M., Billoli, C. et al. A new enteric coated preparation of omega-3 fatty acids for preventing post-surgical recurrence in Crohn's disease. Gastroenterology 1997, 112: A930.
61. Lemann, M., Cuillener, E., Bouhnik, Y. et al. Azathioprine for prevention of Crohn's recurrence after ileal or colonic resection. Gastroenterology 1996, 110: A948.
62. Plevy, S.E., Targan, S.R. Specific management of Crohn's disease. In: Inflammatory Bowel Disease. From Bench to Bedside. Targan, S.R., Shanahan, F. (Eds.). Williams & Wilkins: Baltimore 1994, 582-609.
63. Michelassi, F., Finco, C. Indications for surgery in inflammatory bowel disease: The surgical perspective. In: Inflammatory Bowel Disease, 4th Ed. Kirsner, J.B., Shorter, R.G. (Eds.). Williams & Wilkins: Baltimore 1995, 771-83.
64. Lavy, A., Wisz, G., Adir, Y. et al. Hyperbaric oxygen for perianal Crohn's disease. J Clin Gastroenterol 1994, 19: 202-5.
65. Sands, B.E. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 1997, 3: 95-113.
66. Targan, S.R., Hanauer, S.B., van Derventer, S.J. et al. A short-term study of chimeric mono clonal antibody cA2 to tumor necrosis factor for Crohn's disease. New Engl J Med 1997, 337: 1029-35.
67. van Dulleman, H.M., van Derventer, S.J.H., Hommes, D.W. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109: 129-35.
68. Bicks, R.C., Groshart, K.W., Chandler, R.W. The treatment of severe chronically active Crohn's disease by T8 (suppressor cell) lymphaphoresis. Gastroenterology 1985, 88: A1325.
69. Hanauer, S.B., Schulman, M. Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1995, 24: 523-40.
70. Stronkhorst, A., Radema, S., ten Berge, I. et al. Phase I multiple-dose pilot study of chimeric monoclonal M-T412 (anti-CD-4) antibodies in Crohn's disease. Gastroenterology 1993, 104: A784.
71. Bousvaros, A., Kirschner, B., Werlin, S. et al. Oral tacrolimus treatment of severe colitis in children. Gastroenterology 1997, 112: A941.
72. Fellerman, K., Ludwig, D., Stahl, M. et al. Tacrolimus in steroid refractory inflammatory bowel disease. Gastroenterology 1997, 112: A971.
73. Sandborn, W.J. A preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Gastroenterology 1997, 112: A1080.